# US 2001/0025100 A1 · Translation initiation factor 4AIII, and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025100 A1
- Document ID: US20010025100A1
- Status: Published application
- Kind: A1
- Application number: 09/755,325
- Filed: 2001-01-05
- Published: 2001-09-27
- Earliest claimed: 1998-06-01
- Assignees: The Rockefeller University
- Inventors: Ali Hemmati-Brivanlou; Daniel C. Weinstein
- Web page: https://patentgrep.com/patent/US20010025100A1

## CPC

- C07K 14/4705: {stimulating, promoting or activating activity}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides a vertebrate translation initiation factor (eIF-4AIII), that plays a role in the differentiation of an embryonic cell to an epidermal cell. This translation initiation factor interacts with BMP-4 in a positive regulatory loop. The nucleic acid and amino acid sequences are also disclosed. Also disclosed are methods of using the translation initiation factor, nucleic acids encoding the same, and corresponding antibodies and the like.

## Claims

### Claim 1

An isolated nucleic acid encoding a vertebrate translation initiation factor 4AIII (eIF-4AIII) having an amino acid sequence substantially homologous to that of SEQ ID NO:2.

### Claim 2 (depends on 1)

The isolated nucleic acid of claim 1 wherein the amino acid sequence is SEQ ID NO:2 or SEQ ID NO:2 with a conservative amino acid substitution.

### Claim 3 (depends on 2)

The isolated nucleic acid of claim 2 wherein the nucleic acid contains the coding sequence of SEQ ID NO:1.

### Claim 4 (depends on 1)

The isolated nucleic acid of claim 1 further comprising an heterologous nucleotide sequence.

### Claim 5 (depends on 4)

The isolated nucleic acid of claim 4 wherein the heterologous nucleotide sequence encodes a fusion protein or fusion peptide.

### Claim 6 (depends on 1)

The isolated nucleic acid of claim 1 operatively linked to an expression control sequence.

### Claim 7 (depends on 6)

A unicellular host transformed or transfected with the nucleic acid of claim 6.

### Claim 8 (depends on 7)

A method of expressing the eIF-4AIII comprising culturing the unicellular host of claim 7 in an appropriate cell culture medium under conditions that provide for expression of the protein by the cell.

### Claim 9 (depends on 8)

The method of claim 8 further comprising the step of purifying the eIF-4AIII.

### Claim 10 (depends on 9)

The purified form of the eIF-4AIII obtained by the method of claim 9.

### Claim 11

An isolated nucleic acid containing 15 or more nucleotides that hybridizes to SEQ ID NO:1 under standard hybridization conditions.

### Claim 12 (depends on 11)

The isolated nucleic acid of claim 11 that hybridizes to nucleotides 1 to 90 of the coding region of SEQ ID NO:1 under standard hybridization conditions.

### Claim 13

An isolated vertebrate translation initiation factor 4AIII (eIF-4AIII) having an amino acid sequence substantially homologous to that of SEQ ID NO:2.

### Claim 14 (depends on 13)

The isolated eIF-4AIII-of claim 13 having the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:2 with a conservative amino acid substitution.

### Claim 15 (depends on 13)

The isolated eIF-4AIII of claim 13 containing the amino acid sequence of SEQ ID NO:4.

### Claim 16 (depends on 13)

The isolated eIF-4AIII of claim 13 having a detectable label.

### Claim 17 (depends on 13)

A proteolytic fragment of the isolated eIF-4AIII of claim 13.

### Claim 18 (depends on 17)

A chimeric protein comprising a fusion protein or peptide and the proteolytic fragment of claim 17.

### Claim 19

A chimeric protein comprising a fusion protein or peptide and an eIF-4AIII having an amino acid sequence substantially homologous to that of SEQ ID NO:2.

### Claim 20

An antibody to an isolated vertebrate translation initiation factor 4AIII (eIF-4AIII) having an amino acid sequence substantially homologous to that of SEQ ID NO:2.

### Claim 21 (depends on 20)

The antibody of claim 20 that binds amino acids 1-30 of SEQ ID NO:2.

### Claim 22 (depends on 21)

The antibody of claim 21 which is a monoclonal antibody.

### Claim 23 (depends on 13)

A method for identifying a potential drug that modulates the ability of the eIF-4AIII of claim 13 to induce the transcription of epidermal markers comprising:
(a) injecting an mRNA encoding the eIF-4AIII into an animal pole of a 2-cell stage embryo in the presence of an agent;
(b) isolating the animal pole explant at the late blastula stage;
(c) culturing the animal pole explant until the midneurula stage;
(d) extracting the RNA from the animal pole explant;
(e) assaying for the transcription of an epidermal marker protein; and
(f) comparing the amount of transcription in the presence of the agent relative to in its absence; wherein an agent that enhances or diminishes said transcription relative to in its absence is identified as a potential drug that modulates the ability of the eIF-4AIII to induce the transcription of epidermal markers.

### Claim 24 (depends on 23)

The method of claim 23 wherein said assaying the transcription of the epidermal marker is performed by reverse transcriptase polymerase chain reaction.

### Claim 25 (depends on 23)

The method of claim 23 wherein the 2-cell stage embryo is a xenopus embryo.

### Claim 26 (depends on 23)

The method of claim 23 wherein the animal pole explant is dissociated for 2-6 hours and then reaggregated prior to said culturing of step (c).
